[Research progress of anti-angiogenesis drug targets in diabetic retinopathy]
Related Experiment Video
Updated: Apr 18, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
1Department of Ophthalmology, Second Xiang Ya Hospital, Central South University, Changsha 410000, China.
Abstract:
Diabetic retinopathy is one of the common ocular diseases. One of the pathological characteristic of proliferative diabetic retinopathy is retinal neovascularization which caused visual impairment in diabetic patients. With the anti-VEGF drugs applying in the clinic, it has become one of the main medical treatment of diabetic retinopathy. But it has its limitation. Researchers continue to explore new drug targeting for anti-angiogenesis and try combination therapy or customized treatment. There are many drug targets for anti-angiogenesis, such as promoting angiogenesis factor, integrins and matrix proteinases. Some drugs act on the typical tip cells which is much important in the process of angiogenesis differentiation and proliferation. Overall, these studies opened our view of anti-angiogenesis. The purpose of this article is to summarize the possible drug targets of angiogenesis and the key issues in the study of anti-angiogenic drugs.
Related Concept Videos
Diabetic Retinopathy
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Dipeptidyl Peptidase 4 Inhibitors
Diabetic Nephropathy

